Elevai Labs, Inc. (ELAB) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Elevai Labs, Inc. stock $1.93, price $1.47, upside +31.3%, quality 19 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Elevai Labs, Inc.
ELAB · USCheap (24% below fair value), but weak company and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
36‑month range $1.47 – $1,000,000 · fair‑value band $1.28 – $2.41 · the $1.47 price screens below the $1.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Elevai Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.
Show moreShow less
The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications.
The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Stock analysis
Elevai Labs, Inc. (ELAB) currently trades at $1.47, while our model-based Fair Value estimate is $1.93, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.28 (bear) to $2.41 (bull), the price of $1.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Elevai Labs, Inc. reported revenue of $590K in FY2025 versus $827 in FY2021, a compound +416.8%/yr. Reported net income was −$7.7M in FY2025.
Key figures
Market cap $1.1M Micro · P/S ratio 0.50 · EPS (TTM) $−1,748 · Return on equity −105% · Return on assets (EBIT) −62.5% (5-year average) · Operating margin −470% · Revenue growth (YoY) −45.8% · Free cash flow −$6.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 100% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 31%, ELAB screens cheaper than that median.
Fair Value models
All 1 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch ELAB, get fair value alerts →
Recent news
- Elevai Labs reports Q3 results
- PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025
Compare Elevai Labs, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs ELAB |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs ELAB |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs ELAB |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs ELAB |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs ELAB |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs ELAB |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs ELAB |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs ELAB |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs ELAB |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs ELAB |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Elevai Labs, Inc. (ELAB) overvalued or undervalued?
What is the fair value of ELAB?
What is the quality score of ELAB?
What is the price target for Elevai Labs, Inc. (ELAB)?
What is the Elevai Labs, Inc. stock forecast for 2026?
What is the intrinsic value of Elevai Labs, Inc. (ELAB)?
Is Elevai Labs, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ELAB?
How much is Elevai Labs, Inc. worth?
What do the bullish and bearish scenarios say about ELAB?
How solid is the balance sheet of Elevai Labs, Inc. (ELAB)?
How far is ELAB from its 52-week high?
Which stocks are comparable to Elevai Labs, Inc.?
Is Elevai Labs, Inc. stock attractive at the current price?
How is the fair value of ELAB calculated?
Is it still worth investing in stocks now?
What is the share price of Elevai Labs, Inc. (ELAB)?
What should I pay attention to with Elevai Labs, Inc. right now?
Key figures of Elevai Labs, Inc.
How large is the market capitalisation of Elevai Labs, Inc. (ELAB)?
What is the P/S ratio of Elevai Labs, Inc. (ELAB)?
What are the earnings per share of Elevai Labs, Inc. (ELAB)?
What is the return on equity of Elevai Labs, Inc. (ELAB)?
What is the EBIT return on assets of Elevai Labs, Inc. (ELAB)?
What is the operating margin of Elevai Labs, Inc. (ELAB)?
How fast is revenue growing at Elevai Labs, Inc. (ELAB)?
How much free cash flow does Elevai Labs, Inc. (ELAB) generate?
How much net cash does Elevai Labs, Inc. (ELAB) hold?
Watch Elevai Labs, Inc. in the live analysis
One click puts Elevai Labs, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.